Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026)
Zoetis' (ZTS) quarterly Other Non-Current Liabilities came in at $281.0 million in Q1 2026, up 1.44% year-on-year from $277.0 million in Q1 2025, and up 12.4% on a QoQ basis from $250.0 million in Q4 2025.
Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Other Non-Current Liabilities data on file, last reported at $281.0 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 1.44% year-over-year to $281.0 million in Q1 2026; TTM through Mar 2026 was $281.0 million, a 1.44% increase from a year earlier, with the FY2025 full-year figure at $250.0 million, down 8.09% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $281.0 million, up from $250.0 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for ZTS reached as high as $281.0 million in Q1 2026 and fell as low as $216.0 million in Q1 2023.
- Historically, Other Non-Current Liabilities has averaged $249.5 million across 5 years, with a median of $250.0 million in 2025.
- Across the five-year window, Other Non-Current Liabilities declined 10.73% in 2022 and advanced 23.42% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $258.0 million in 2022, then decreased by 8.14% to $237.0 million in 2023, then grew by 14.77% to $272.0 million in 2024, then dropped by 8.09% to $250.0 million in 2025, then gained by 12.4% to $281.0 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $281.0 million in Q1 2026, $250.0 million in Q4 2025, and $264.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 281.00 Mn |
| Dec 31, 2025 | 250.00 Mn |
| Sep 30, 2025 | 264.00 Mn |
| Jun 30, 2025 | 274.00 Mn |
| Mar 31, 2025 | 277.00 Mn |
| Dec 31, 2024 | 272.00 Mn |
| Sep 30, 2024 | 274.00 Mn |
| Jun 30, 2024 | 222.00 Mn |
| Mar 31, 2024 | 228.00 Mn |
| Dec 31, 2023 | 237.00 Mn |
| Sep 30, 2023 | 259.00 Mn |
| Jun 30, 2023 | 217.00 Mn |
| Mar 31, 2023 | 216.00 Mn |
| Dec 31, 2022 | 258.00 Mn |
| Sep 30, 2022 | 239.00 Mn |
| Jun 30, 2022 | 233.00 Mn |
| Mar 31, 2022 | 241.00 Mn |
| Dec 31, 2021 | 239.00 Mn |
| Sep 30, 2021 | 251.00 Mn |
| Jun 30, 2021 | 261.00 Mn |